the alphamab r&d team has successfully developed integrated technology platforms for biologics through a deep understanding of protein structure and function, combined with the bioinformatics analysis and prediction. these technology platforms include the proprietary glycan-specific conjugation platform, linker-payload platform, proprietary bispecific antibody platform, subcutaneous high concentration formulation platform and single-domain antibody platform.
the innovative technology platforms support a focus on multidimensional antibody modification technologies, enabling the independent development of a product pipeline with significant differentiated advantages, which constitutes the core competitive strength of alphamab.
